What are you submitting to AEJMC?

I thought it would be interesting and useful if people responded in the comments section about what they're doing for AEJMC's deadline of April 1st. I'll start by posting in the comments first -- please join in.

AU 07 class

Welcome to the new class of graduate students. We love it here and we hope you will too. I think you will find what we already know ......you have selected the best education possible and the greatest grad students to work with :)

COPS student publishes in Public Opinion Quarterly

Congratulations to Teresa Myers for "Twenty years of public opinion about global warming" just accepted for publication in Public Opinion Quarterly. This paper was a collaborative effort between Teresa and American University professor Matthew Nisbet. Pieces such as this that track public opinion over decades tend to be well received and highly cited. This paper illustrates what our students are capable of right out of the starting gate (Teresa was a first year M.A. student when this paper was first drafted) and what can be accomplished when you immerse yourself in the kind of research culture that is OSU and COPS.

Welcoming the First New Student for AU '07 to COPS

She has already joined the COPS blog, but I wanted to give a formal welcome to Laurel Gleason as a new PhD student in the School of Communication starting in Autumn 2007. Laurel is the first of what I expect to be several students who choose OSU for graduate study. Laurel's interests lie in how individuals construct political meaning out of the information and cues the media disseminates, and how such constructed meaning relates to political engagment. Please welcome Laurel, and look here for future announcements as we receive commitments from students who will be joining us next year.

Lux Biosciences starts uveitis pivotal trial - EyeWorld Week March 6, 2007

A next-generation calcineurin inhibitor for the treatment of uveitis has entered pivotal trials, according to developer Lux Biosciences (Jersey City, N.J.).
LUMINATE (Lux Uveitis Multicenter Investigation of a New Approach to Treatment) consists of three controlled, double masked studies of LX211 in different forms of active uveitis and to investigate its use in maintaining control in patients with quiescent disease, the company said. A total of 45 sites in the U.S. and Europe will participate, with patient enrollment estimated to be 500. Efficacy will be measured at 6 months, assessing the degree of inflammation in the anterior and posterior chambers. The company expects results from the pivotal trials in 2008, with regulatory approval sought in late 2008.
LX211 is exclusively licensed to Lux by Isotechnika (Edmonton, Canada); Isotechnika is developing the compound for psoriasis and solid organ transplantation.

Another COPS Award Winner at ICA

In addition to the paper by Lindsay Hoffman and Tiffany Thomson on the top student paper session in the Mass Communication division at the ICA conference in San Francisco in May, I have just learned that Myiah Hively will be presenting a co-authored paper in the top faculty paper session in the Mass Communication division. Having COPS students involved in both the top student and top faculty paper sessions in Mass Communication should be no surprise, given that School of Communication at OSU has recently been ranked in the top three programs in the country in Mass Communication. Congratulations Myiah!